Dr Lal PathLabs

May 17, 2019

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Outcome of Board Meeting held on May 17, 2019

Ref: Compliances under SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 ("Listing Regulations")

Dear Sir/Madam,

Please take note that the Board of Directors in their meeting held today i.e. May 17, 2019 approved following matters:

1. The Audited Standalone and Consolidated Financial Results ("Results") of the Company for the Quarter and Financial Year ended March 31, 2019. A copy of the signed Results along with Auditors Report and Declaration in respect of Audit Report with unmodified opinion under Regulation 33 of the Listing Regulations is attached herewith.

2. Convening of 25th Annual General Meeting (AGM) of the Company on Monday, August 12, 2019.

3. Recommendation of final dividend of Rs. 3/- per equity share (@ 30 % on a face value of Rs. 10/- per share) for the year ended March 31, 2019. The dividend, if approved by the shareholders at the ensuing Annual General Meeting (AGM) will be paid on or after August 21, 2019.

4. Pursuant to Regulation 42 of Listing Regulations, the Register of Members and Share Transfer books of the Company will remain closed from Tuesday, August 6, 2019 to Monday, August 12, 2019 (both days inclusive) for the purpose of 25th AGM and payment of dividend (if approved by the Shareholders).

Symbol	Type of security	Book Closure both days inclusive	Record Date	Purpose
NSE - LALPATHLAB BSE – 539524	Equity	Tuesday, August 6, 2019 To Monday, August 12, 2019	Not Applicable	1. 25th Annual General Meeting (AGM) 2. Payment of dividend, if approved at the ensuing Annual General Meeting

Dr. Lal PathLabs Limited

Regd. Office: Dr. Lal PathLabs Ltd., Block E, Sector-18, Rohini, New Delhi - 110085, ✆ +91-11-30258600, **Fax:** +91-11-2788-2134
Corporate Office: Dr. Lal PathLabs Ltd., 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram - 122 001, Haryana ✆ +91-124-3016-500, **Fax:** +91-124-4234-468
E-mail: lalpathlabs@lalpathlabs.com, **Web:** www.lalpathlabs.com, **CIN No.:** L74899DL1995PLC065388

5. The cut-off date for the purpose of payment of dividend and voting at the ensuing Annual General Meeting will be Monday, August 5, 2019.

6. Based on the recommendations of the Nomination and Remuneration Committee and subject to the approval of shareholders at the ensuing AGM, the Board of Directors appointed Dr. Archana Lal Erdmann as an Additional Director (Non-Executive), liable to retire by rotation, on the Board of the Company w.e.f. May 17, 2019.

   Details as required under SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 are attached herewith as Annexure A.

7. In line with good Corporate Governance Practices, Mr. Sunil Varma, Independent Director and Chairman of the Audit Committee of the Company has also been designated as Lead Independent Director w.e.f May 17, 2019.

8. The Board Meeting commenced at 11 A.M. and concluded at 2:30 P.M.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary and Legal Head

Encl: As above

Annexure – A

Reason for change	Appointment
Date of appointment	May 17, 2019
Brief Profile	Archana Lal Erdmann holds an MBBS degree (Bachelor of Medicine and Bachelor of Surgery) from Bharati Vidyapeeth Medical College, Pune and completed M.D. & DNB (Pathology) from Sri Ramachandra University, Chennai, Tamil Nadu. Dr. Archana is an American board certified Geneticist, and completed fellowships in Clinical Cytogenetics and Clinical Molecular Genetics from Stanford University School of Medicine, California, USA. Dr. Archana brings 10 years of experience in laboratory genetics and genomics testing with a focus on research for genetic tests for both inherited and acquired genetic diseases, developing next generation sequencing-based tests for genotyping tumors, clinical variant curation, and expanding the scope of genetic testing with the goal of identifying patients eligible for novel targeting therapies.
Disclosure of relationships between directors	Dr. Archana Lal Erdmann is daughter of (Hony) Brig. Dr. Arvind Lal and Dr. Vandana Lal, Promoter Directors of the Company

Note - Dr. Archana Lal Erdmann is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other authority

Dr. Lal PathLabs Limited